Anbio Biotechnology Class A Ordinary Shares logo

Anbio Biotechnology Class A Ordinary Shares

NNNN | NASDAQ
Chart Builder DCF Calculator
$5.63
-$0.05 (-0.88%)
Sep 22, 2026, 1:00 PM ET · Market open
Fiscal Quarter
Period Ending
Q4 2025
Dec 30, 2025
Q2 2025
Jun 29, 2025
Q4 2024
Dec 30, 2024
Q2 2024
Jun 29, 2024
Q4 2023
Dec 30, 2023
Q2 2023
Jun 29, 2023
Q4 2022
Dec 30, 2022
Cash & Equivalents
7.77M 6.28M 11.76M 10.31M 9.69M 10.56M 7.1M
Short-Term Investments
4.13M 9.49M n/a n/a n/a n/a 1.57M
Long-Term Investments
n/a n/a n/a n/a n/a n/a n/a
Other Long-Term Assets
n/a n/a 387.44K 176.99K 62.14K 276.8K 2.99K
Receivables
3.66M 4.36M 1.06M 4.62M 1.88M 3.58K 3.58K
Inventory
n/a n/a n/a n/a n/a n/a 353.87K
Other Current Assets
n/a 425.12K n/a n/a n/a n/a n/a
Total Current Assets
30.24M 32.49M 18.53M 18.77M 15.75M 15.15M 13.94M
Property-Plant & Equipment
n/a n/a n/a n/a n/a 3.27K 12.06K
Goodwill & Intangibles
n/a n/a n/a n/a n/a n/a n/a
Total Long-Term Assets
n/a n/a 387.44K 176.99K 62.14K 280.07K 15.05K
Total Assets
30.24M 32.49M 18.92M 18.94M 15.81M 15.43M 13.96M
Account Payables
n/a 70.84K 1.63M 478.96K 827.15K 1.31M 1.41M
Deferred Revenue
n/a n/a n/a n/a n/a n/a n/a
Short-Term Debt
n/a n/a n/a n/a n/a n/a n/a
Other Current Liabilities
n/a 83.08K n/a n/a n/a n/a n/a
Total Current Liabilities
87.84K 153.92K 1.73M 527.75K 993.06K 1.34M 1.41M
Long-Term Debt
n/a n/a n/a n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a n/a n/a n/a n/a
Total Long-Term Liabilities
n/a n/a n/a n/a n/a n/a n/a
Total Liabilities
87.84K 153.92K 1.73M 527.75K 993.06K 1.34M 1.41M
Total Debt
n/a n/a n/a n/a n/a n/a n/a
Book Value
30.16M 32.34M 17.19M 18.42M 14.82M 14.09M n/a
Book Value Per Share
0.69 0.74 0.41 0.44 0.35 0.33 n/a
Common Stock
14.39K 16.89K 14.23K 14.23K 14.23K 14.23K n/a
Retained Earnings
23.58M 24.62M 17.17M 18.4M 14.8M 14.07M 12.55M
Comprehensive Income
n/a n/a n/a n/a n/a n/a n/a
Shareholders Equity
30.16M 32.34M 17.19M 18.42M 14.82M 14.09M 12.55M
Total Investments
4.13M 9.49M n/a n/a n/a n/a 1.57M

© 2026 bestshares.com. All rights reserved.